Last reviewed 2026-05-29 · How we verify

Amiridine (IPIDACRINE)

Phase 2 active Small molecule ✓ Verified May 2026 Quality 28/100

Amiridine (generic name: IPIDACRINE) is a ipidacrine drug. It is currently in Phase 2 development for Alzheimer's disease.

Amiridine works by inhibiting the enzyme Acetylcholinesterase, which breaks down the neurotransmitter acetylcholine.

Amiridine is a small molecule. It is also known by the synonyms IPIDACRINA, IPIDACRINE, and IPIDACRINE.

Likelihood of approval

12.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
CNS / neurology attrition -3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	IPIDACRINE
Drug class	ipidacrine
Target	Acetylcholinesterase
Modality	Small molecule
Therapeutic area	Neuroscience
Phase	Phase 2

Mechanism of action

Think of acetylcholine like a key that unlocks memories and helps us learn. When acetylcholinesterase breaks it down, the key is destroyed and can't do its job. By blocking this enzyme, Amiridine allows more acetylcholine to build up in the brain, helping to improve memory and cognitive function.

Approved indications

Alzheimer's disease

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Amiridine CI brief — competitive landscape report
Amiridine updates RSS · CI watch RSS

Frequently asked questions about Amiridine

What is Amiridine?

Amiridine (IPIDACRINE) is a ipidacrine drug, indicated for Alzheimer's disease.

How does Amiridine work?

Amiridine works by inhibiting the enzyme Acetylcholinesterase, which breaks down the neurotransmitter acetylcholine.

What is Amiridine used for?

Amiridine is indicated for Alzheimer's disease.

What is the generic name of Amiridine?

IPIDACRINE is the generic (nonproprietary) name of Amiridine.

What drug class is Amiridine in?

Amiridine belongs to the ipidacrine class. See all ipidacrine drugs at /class/ipidacrine.

What development phase is Amiridine in?

Amiridine is in Phase 2.

What does Amiridine target?

Amiridine targets Acetylcholinesterase and is a ipidacrine.

Drug class: All ipidacrine drugs
Target: All drugs targeting Acetylcholinesterase
Therapeutic area: All drugs in Neuroscience
Indication: Drugs for Alzheimer's disease

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing